<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="deo270048" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">DEN Open</journal-id><journal-id journal-id-type="iso-abbrev">DEN Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2692-4609</journal-id><journal-id journal-id-type="publisher-id">DEO2</journal-id><journal-title-group><journal-title>DEN Open</journal-title></journal-title-group><issn pub-type="epub">2692-4609</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39741901</article-id><article-id pub-id-type="pmc">PMC11687558</article-id>
<article-id pub-id-type="doi">10.1002/deo2.70048</article-id><article-id pub-id-type="publisher-id">DEO270048</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparison of sedation with pentazocine or pethidine hydrochloride for endoscopic ultrasonography in outpatients: A single&#x02010;center retrospective study</article-title><alt-title alt-title-type="left-running-head">URABE <sc>et&#x000a0;al</sc>.</alt-title></title-group><contrib-group><contrib id="deo270048-cr-0001" contrib-type="author"><name><surname>Urabe</surname><given-names>Makiko</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-8033-3158</contrib-id><xref rid="deo270048-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270048-cr-0002" contrib-type="author" corresp="yes"><name><surname>Ikezawa</surname><given-names>Kenji</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7517-8960</contrib-id><xref rid="deo270048-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>ikezawa-ke@oici.jp</email></address></contrib><contrib id="deo270048-cr-0003" contrib-type="author"><name><surname>Seiki</surname><given-names>Yusuke</given-names></name><xref rid="deo270048-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270048-cr-0004" contrib-type="author"><name><surname>Watsuji</surname><given-names>Ko</given-names></name><xref rid="deo270048-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270048-cr-0005" contrib-type="author"><name><surname>Kawamoto</surname><given-names>Yasuharu</given-names></name><xref rid="deo270048-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270048-cr-0006" contrib-type="author"><name><surname>Hirao</surname><given-names>Takeru</given-names></name><xref rid="deo270048-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270048-cr-0007" contrib-type="author"><name><surname>Kai</surname><given-names>Yugo</given-names></name><xref rid="deo270048-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270048-cr-0008" contrib-type="author"><name><surname>Takada</surname><given-names>Ryoji</given-names></name><xref rid="deo270048-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270048-cr-0009" contrib-type="author"><name><surname>Yamai</surname><given-names>Takuo</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5448-4763</contrib-id><xref rid="deo270048-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270048-cr-0010" contrib-type="author"><name><surname>Mukai</surname><given-names>Kaori</given-names></name><xref rid="deo270048-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270048-cr-0011" contrib-type="author"><name><surname>Nakabori</surname><given-names>Tasuku</given-names></name><xref rid="deo270048-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270048-cr-0012" contrib-type="author"><name><surname>Uehara</surname><given-names>Hiroyuki</given-names></name><xref rid="deo270048-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270048-cr-0013" contrib-type="author"><name><surname>Ohkawa</surname><given-names>Kazuyoshi</given-names></name><xref rid="deo270048-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="deo270048-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Hepatobiliary and Pancreatic Oncology</named-content>
<institution>Osaka International Cancer Institute</institution>
<city>Osaka</city>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Kenji Ikezawa, Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3&#x02010;1&#x02010;69 Otemae, Chuo&#x02010;ku, Osaka 541&#x02010;8567, Japan.<break/> Email: <email>ikezawa-ke@oici.jp</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>5</volume><issue seq="46">1</issue><issue-id pub-id-type="doi">10.1002/deo2.v5.1</issue-id><elocation-id>e70048</elocation-id><history>
<date date-type="rev-recd"><day>02</day><month>12</month><year>2024</year></date>
<date date-type="received"><day>10</day><month>7</month><year>2024</year></date>
<date date-type="accepted"><day>12</day><month>12</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">DEN Open</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DEO2-5-e70048.pdf"/><abstract><title>Abstract</title><sec id="deo270048-sec-0010"><title>Objectives</title><p>Endoscopic ultrasonography (EUS) plays an important role in the diagnosis of pancreatobiliary diseases. However, an appropriate sedation method for EUS has not been established. Therefore, this study aimed to examine the safety and complications of sedation with pentazocine or pethidine hydrochloride for outpatient diagnostic EUS.</p></sec><sec id="deo270048-sec-0020"><title>Methods</title><p>We retrospectively reviewed 1302 consecutive cases in our department that underwent outpatient diagnostic EUS between April 2019 and September 2021. Until June 2020, EUS was performed under sedation with midazolam and pentazocine (pentazocine group) in principle; after June 2020, sedation with midazolam and pethidine hydrochloride (pethidine hydrochloride group) was used. A cohort of patients with comparable backgrounds was identified using propensity score matching.</p></sec><sec id="deo270048-sec-0030"><title>Results</title><p>A total of 486 cases were included in this study. Sedation&#x02010;related adverse events during the endoscopic procedures were not significantly different between the groups. The median time spent in the recovery room after EUS was significantly shorter in the pethidine hydrochloride group than in the pentazocine group (69 versus vs. 77 min; <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001). The frequency of nausea or vomiting after EUS was significantly lower in the pethidine hydrochloride group than in the pentazocine group (0% [0/486] vs. 6.2% [29/486]; <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001). The frequency of readmission to the recovery room after discharge was significantly lower in the pethidine group than in the pentazocine group (0 [0%] vs. 18 [3.7%], respectively; <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001).</p></sec><sec id="deo270048-sec-0040"><title>Conclusions</title><p>The combination of midazolam and pethidine hydrochloride is a more favorable anesthetic than the combination of midazolam and pentazocine for diagnostic EUS in outpatients.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="deo270048-kwd-0001">EUS</kwd><kwd id="deo270048-kwd-0002">midazolam</kwd><kwd id="deo270048-kwd-0003">pentazocine</kwd><kwd id="deo270048-kwd-0004">pethidine hydrochloride</kwd><kwd id="deo270048-kwd-0005">sedation</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>None</funding-source></award-group></funding-group><counts><fig-count count="0"/><table-count count="4"/><page-count count="8"/><word-count count="4465"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:27.02.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="deo270048-sec-0050"><title>INTRODUCTION</title><p>In recent years, the number of patients with pancreatic and biliary tract cancer has been increasing.<xref rid="deo270048-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="deo270048-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Pancreatic cancer has a poor prognosis because early diagnosis of pancreatic cancer is often difficult with conventional diagnostic imaging modalities, e.g., computed tomography and magnetic resonance imaging.<xref rid="deo270048-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="deo270048-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> Endoscopic ultrasonography (EUS) can detect small pancreatic cancer without the use of ionizing radiation or contrast agents.<xref rid="deo270048-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="deo270048-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> EUS observation using new techniques, e.g., elastography and detective flow imaging, enhances the diagnostic capabilities of EUS<xref rid="deo270048-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="deo270048-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> and plays an important role in the surveillance of pancreatic cancer.<xref rid="deo270048-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="deo270048-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> In patients with biliary tract cancer, EUS provides valuable information regarding the extent of the cancer and lymph node metastasis.<xref rid="deo270048-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> EUS is also useful in the differentiation between malignant and benign biliary strictures.<xref rid="deo270048-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Thus, the importance of EUS for pancreatobiliary diseases has been increasing.</p><p>Sedated endoscopy has improved patient acceptance and satisfaction and has contributed to the improvement of diagnostic procedure quality and treatment outcomes.<xref rid="deo270048-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="deo270048-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="deo270048-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="deo270048-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> The optimal level of sedation for endoscopic procedures is moderate, which allows patients to maintain ventilatory and cardiovascular functions and to respond purposefully to verbal or light tactile stimulation.<xref rid="deo270048-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="deo270048-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Sedation lowers the level of consciousness, whereas analgesia reduces pain without lowering the level of consciousness.<xref rid="deo270048-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> If sedatives alone do not provide adequate sedation, a combination of sedatives and analgesics may be effective.<xref rid="deo270048-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="deo270048-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> According to national survey reports in Japan, the most commonly used sedative is midazolam, and the most commonly used analgesics are pentazocine and pethidine hydrochloride.<xref rid="deo270048-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> The combination of midazolam and pentazocine is the conventional method used in Japan, but few studies have compared sedation with pentazocine to sedation with other analgesics.<xref rid="deo270048-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="deo270048-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> In this study, we retrospectively examined the safety and complications of sedation with pentazocine or pethidine hydrochloride for diagnostic EUS in outpatients.</p></sec><sec id="deo270048-sec-0060"><title>METHODS</title><sec id="deo270048-sec-0070"><title>Study design and patients</title><p>We retrospectively reviewed 1302 consecutive cases who underwent diagnostic EUS in an outpatient setting at our hospital between April 2019 and September 2021. Until June 2020, in principle, the endoscopy was performed under sedation with a combination of midazolam and pentazocine; after June 2020, sedation with midazolam and pethidine hydrochloride was used. Pentazocine or pethidine hydrochloride was administered intravenously in addition to midazolam at the initiation of endoscopy.</p><p>This study was approved by the Institutional Review Board of Osaka International Cancer Institute (approval number: 20117&#x02010;6) and was designed and executed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments.</p></sec><sec id="deo270048-sec-0080"><title>EUS procedures, monitoring, and recovery</title><p>All EUS procedures were performed by endoscopists in our department using a linear&#x02010;array echoendoscope (GF&#x02010;UCT260; Olympus Medical Systems). After the initial administration of sedatives and analgesics by endoscopists, endoscope insertion was started when the endoscopist judged the Ramsey Sedation scale score as 5 or 6. The addition of sedatives or analgesics was performed by endoscopists or nurses when deemed necessary by endoscopists to maintain appropriate sedation. Each endoscopist determined the doses of midazolam, pentazocine, and pethidine hydrochloride. The patients received 2 L/min (min) oxygen via a nasal cannula from procedure initiation, and their vital signs were recorded and monitored every 5&#x000a0;min during the procedure. Oxygen saturation was recorded using a pulse oximeter (Nihon Kohden Co.). Cardiac function was measured using electrocardiography, and blood pressure was measured using an automatic inflatable cuff (Nihon Kohden Co.). Nurses recorded the procedure time (defined as the period between endoscope insertion and extubation), amount of medication, and sedation&#x02010;related adverse events during endoscopic procedures. Respiratory complications were defined as an oxygen saturation level less than 90%, requiring supplemental oxygen. Circulatory complications were defined as a decrease in systolic blood pressure below 90&#x000a0;mmHg, requiring the administration of intravenous fluids. Discontinuation of EUS was defined as cases where the endoscopists judged it unsafe or inappropriate to proceed. The use of antagonistic agent (flumazenil) was decided at the discretion of each endoscopist, such as in cases of reduced patient arousal. After EUS was completed, the patients were moved from the endoscopy room to the recovery room, which was part of the endoscopy suite, and they continued to be monitored. The discharge from the recovery room was determined by nurses based on an assessment of the anesthesia recovery criteria in our department. The anesthesia recovery criteria require that (1) the patient is able to say his name in response to calls; (2) the patient is able to take deep breaths and cough; (3) the patient can maintain a saturation of peripheral oxygen of&#x000a0;&#x02265;92% without oxygen; (4) the patient has a systolic blood pressure of&#x000a0;&#x02265;90&#x000a0;mmHg; (5) the patient has a heart rate of&#x000a0;&#x02265;50 bpm; (6) the patient has a healthy complexion and no nausea or vomiting; (7) at least 45&#x000a0;min have passed since the endoscopy extubation; (8) the patient can move his/her limbs freely and can walk independently without staggering. If all eight discharge criteria were met, the patient was judged to be ready for discharge. The time spent in the recovery room was calculated as the time from admission to the recovery room to discharge from the recovery room. The frequency of readmission to the recovery room after discharge from the recovery room was also calculated.</p></sec><sec id="deo270048-sec-0090"><title>Statistical analysis</title><p>Categorical variables are expressed as percentages, whereas continuous variables are presented as medians and interquartile ranges (IQRs). Baseline characteristics (patient sex, patient age, patient body mass index (BMI), performance status, reasons for diagnostic EUS, and EUS operator), procedure&#x02010;related outcomes (procedure time, doses of midazolam, and sedation&#x02010;related adverse events), duration of stay in the recovery room, nausea or vomiting after EUS, and readmission to the recovery room were compared using chi&#x02010;square and Fisher exact tests for categorical variables or the Mann&#x02013;Whitney U&#x02010;test for continuous variables. The EUS operators were classified as experts and trainees. Experts were defined as endoscopists who had performed EUS for&#x000a0;&#x0003e;3 years.</p><p>Propensity score matching was performed to identify patients with similar baseline characteristics. Age, sex, BMI, and operator of EUS were used as factors in the propensity score using logistic regression analysis. Briefly, a 1:1 matching protocol without replacement using a greedy matching algorithm was used with the caliper width set at 0.2 of the standard deviation of the logit of the propensity score. Standardized differences for each baseline covariate were calculated to evaluate balance before and after matching. Small imbalances were indicated by normalized differences of&#x000a0;&#x0003c;0.10 for each covariate.<xref rid="deo270048-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> To examine factors associated with readmission to the recovery room, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using univariate and multivariate logistic regression analyses. Factors with a <italic toggle="yes">p</italic>&#x02010;value&#x000a0;&#x0003c;0.20 on univariate analysis were entered into the multivariate analyses.&#x000a0;EZR (Saitama Medical Center, Jichi Medical University), a graphical interface for R, and R Commander software package for Windows (version 1.54) were used to perform all statistical analyses.<xref rid="deo270048-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Statistical significance was set at <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.05.</p></sec></sec><sec id="deo270048-sec-0100"><title>RESULTS</title><sec id="deo270048-sec-0110"><title>Baseline characteristics</title><p>A total of 1302 diagnostic EUS procedures were performed in our endoscopy unit during the study period. Pentazocine was used as an analgesic in 535 cases (pentazocine group), and pethidine hydrochloride was used in 767 cases (pethidine hydrochloride group). The baseline characteristics of the study population are summarized in Table&#x000a0;<xref rid="deo270048-tbl-0001" ref-type="table">1</xref>. Before performing the propensity score&#x02010;matched analyses, we found marked differences in sex and EUS operators between the groups. After propensity score&#x02010;matched analyses, 486 patients were included in each group, and there were no significant differences in any of the variables in Table&#x000a0;<xref rid="deo270048-tbl-0002" ref-type="table">2</xref>. The standardized differences in age, sex, BMI, and EUS operator were&#x000a0;&#x0003c;0.1 after propensity score&#x02010;matched analyses.</p><table-wrap position="float" id="deo270048-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Baseline characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<p>Pentazocine</p>
<p>
<italic toggle="yes">N</italic>&#x000a0;= 535</p>
</th><th align="left" rowspan="1" colspan="1">
<p>Pethidine hydrochloride</p>
<p>
<italic toggle="yes">N</italic>&#x000a0;= 767</p>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">347 (64.9)</td><td align="center" rowspan="1" colspan="1">330 (43.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">188 (35.1)</td><td align="center" rowspan="1" colspan="1">437 (57.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, years, median (IQR),</td><td align="center" rowspan="1" colspan="1">69 (60&#x02013;74)</td><td align="center" rowspan="1" colspan="1">69 (59&#x02013;73)</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>, median (IQR)</td><td align="center" rowspan="1" colspan="1">22.5 (20.6&#x02013;25.1)</td><td align="center" rowspan="1" colspan="1">22.5 (20.4&#x02013;25.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Performance status, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">0 or 1</td><td align="center" rowspan="1" colspan="1">535</td><td align="center" rowspan="1" colspan="1">766</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2&#x0003c;</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Reason for diagnostic EUS, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pancreatic tumor</td><td align="center" rowspan="1" colspan="1">201 (37.6)</td><td align="center" rowspan="1" colspan="1">303 (39.5)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Intraductal papillary mucinous neoplasm</td><td align="center" rowspan="1" colspan="1">138 (25.8)</td><td align="center" rowspan="1" colspan="1">200 (26.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pancreatic cysts</td><td align="center" rowspan="1" colspan="1">121 (22.6)</td><td align="center" rowspan="1" colspan="1">176 (23.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pancreatic neuroendocrine tumor</td><td align="center" rowspan="1" colspan="1">13 (2.4)</td><td align="center" rowspan="1" colspan="1">16 (2.1)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Papillary tumor</td><td align="center" rowspan="1" colspan="1">32 (6.0)</td><td align="center" rowspan="1" colspan="1">37 (4.8)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Biliary tract tumor</td><td align="center" rowspan="1" colspan="1">13 (2.4)</td><td align="center" rowspan="1" colspan="1">16 (2.1)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Gallbladder tumor</td><td align="center" rowspan="1" colspan="1">7 (1.3)</td><td align="center" rowspan="1" colspan="1">12 (1.6)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Intraabdominal tumor</td><td align="center" rowspan="1" colspan="1">3 (0.6)</td><td align="center" rowspan="1" colspan="1">3 (0.4)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Duodenal tumor</td><td align="center" rowspan="1" colspan="1">1 (0.2)</td><td align="center" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lymph node</td><td align="center" rowspan="1" colspan="1">6 (1.1)</td><td align="center" rowspan="1" colspan="1">2 (0.3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Common bile duct stone</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">2 (0.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Operator of EUS, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Expert</td><td align="center" rowspan="1" colspan="1">228 (42.6)</td><td align="center" rowspan="1" colspan="1">267 (34.8)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Trainee</td><td align="center" rowspan="1" colspan="1">307 (57.4)</td><td align="center" rowspan="1" colspan="1">500 (65.2)</td></tr></tbody></table><table-wrap-foot><fn id="deo270048-tbl1-note-0001"><p>Abbreviations: EUS, endoscopic ultrasonography; IQR, interquartile range.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="deo270048-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Baseline characteristics before and after propensity score matching.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="4" style="border-bottom:solid 1px #000000" rowspan="1">Original Data Set</th><th align="left" colspan="4" style="border-bottom:solid 1px #000000" rowspan="1">Matched Data Set</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Pentazocine <italic toggle="yes">N</italic> = 535</th><th align="left" rowspan="1" colspan="1">Pethidine hydrochloride <italic toggle="yes">N</italic> = 767</th><th align="left" rowspan="1" colspan="1">SMD</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>&#x02010;value</th><th align="left" rowspan="1" colspan="1">Pentazocine <italic toggle="yes">N</italic> = 486</th><th align="left" rowspan="1" colspan="1">Pethidine hydrochloride <italic toggle="yes">N</italic> = 486</th><th align="left" rowspan="1" colspan="1">SMD</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex, n (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">347 (64.9)</td><td align="left" rowspan="1" colspan="1">330 (43.0)</td><td align="left" rowspan="1" colspan="1">0.449</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">300 (61.7)</td><td align="left" rowspan="1" colspan="1">300 (61.7)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">188 (35.1)</td><td align="left" rowspan="1" colspan="1">437 (57.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">186 (38.3)</td><td align="left" rowspan="1" colspan="1">186 (38.3)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age, years, median (IQR)</td><td align="left" rowspan="1" colspan="1">69 (60&#x02013;74)</td><td align="left" rowspan="1" colspan="1">69 (59&#x02013;73)</td><td align="left" rowspan="1" colspan="1">0.033</td><td align="left" rowspan="1" colspan="1">0.554</td><td align="left" rowspan="1" colspan="1">69 (60&#x02013;74)</td><td align="left" rowspan="1" colspan="1">68 (59&#x02013;73)</td><td align="left" rowspan="1" colspan="1">0.062</td><td align="left" rowspan="1" colspan="1">0.337</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>, median (IQR)</td><td align="left" rowspan="1" colspan="1">22.5 (20.6&#x02013;27.1)</td><td align="left" rowspan="1" colspan="1">22.5 (20.4&#x02013;25.0)</td><td align="left" rowspan="1" colspan="1">0.087</td><td align="left" rowspan="1" colspan="1">0.126</td><td align="left" rowspan="1" colspan="1">22.5 (20.7&#x02013;25.1)</td><td align="left" rowspan="1" colspan="1">22.9 (20.8&#x02013;25.0)</td><td align="left" rowspan="1" colspan="1">0.003</td><td align="left" rowspan="1" colspan="1">0.968</td></tr><tr><td align="left" rowspan="1" colspan="1">Operator of EUS, n (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Expert</td><td align="left" rowspan="1" colspan="1">228 (54.6)</td><td align="left" rowspan="1" colspan="1">267 (34.8)</td><td align="left" rowspan="1" colspan="1">0.161</td><td align="left" rowspan="1" colspan="1">0.005</td><td align="left" rowspan="1" colspan="1">186 (38.3)</td><td align="left" rowspan="1" colspan="1">186 (38.3)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Trainee</td><td align="left" rowspan="1" colspan="1">307 (57.4)</td><td align="left" rowspan="1" colspan="1">500 (65.2)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">300 (61.7)</td><td align="left" rowspan="1" colspan="1">300 (61.7)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="deo270048-tbl2-note-0001"><p>Abbreviations: BMI, body mass index; EUS, endoscopic ultrasonography; IQR, interquartile range; SMD, standardized mean difference.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo270048-sec-0120"><title>Procedure&#x02010;related outcomes</title><p>The procedure&#x02010;related outcomes of this study after propensity score matching are summarized in Table&#x000a0;<xref rid="deo270048-tbl-0003" ref-type="table">3</xref>. The procedure time was not significantly different between the groups (median [IQR], pethidine hydrochloride group: 23&#x000a0;min [18&#x02013;29&#x000a0;min] vs. pentazocine group: 22&#x000a0;min [16&#x02013;28&#x000a0;min]; <italic toggle="yes">p&#x000a0;</italic>=&#x000a0;0.072). The median pre&#x02010;EUS dose of pentazocine was 15&#x000a0;mg, whereas the median pre&#x02010;EUS dose of pethidine hydrochloride was 35&#x000a0;mg. The median pre&#x02010;EUS dose of midazolam was significantly lower in the pethidine hydrochloride group than in the pentazocine group (median [IQR], 0.050&#x000a0;mg/kg [0.043&#x02013;0.061&#x000a0;mg/kg] vs. 0.058&#x000a0;mg/kg [0.048&#x02013;0.069&#x000a0;mg/kg]; <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001). The median total dose of midazolam was significantly lower in the pethidine hydrochloride group than in the pentazocine group (median [IQR], 0.068&#x000a0;mg/kg [0.057&#x02013;0.080&#x000a0;mg/kg] vs. 0.075&#x000a0;mg/kg [0.061&#x02013;0.095&#x000a0;mg/kg]; <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001). There were no deaths or serious complications that required life&#x02010;saving treatment during the present study period. Although one patient in the pethidine hydrochloride group discontinued EUS because of respiratory depression, there was no significant difference in the frequency of sedation&#x02010;related adverse events during the endoscopic procedures between the groups. The frequency of administration of flumazenil after the endoscopic procedures did not differ significantly between the groups (pethidine hydrochloride group: 33 cases (6.7%) vs. pentazocine group: 32 cases (6.6%); <italic toggle="yes">p&#x000a0;</italic>=&#x000a0;0.898).</p><table-wrap position="float" id="deo270048-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Procedure&#x02010;related outcomes (after propensity score matching).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<p>Pentazocine</p>
<p>
<italic toggle="yes">N</italic>&#x000a0;= 486</p>
</th><th align="left" rowspan="1" colspan="1">
<p>Pethidine hydrochloride</p>
<p>
<italic toggle="yes">N</italic>&#x000a0;= 486</p>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Procedure time, minute, median (IQR)</td><td align="center" rowspan="1" colspan="1">22 (16&#x02013;28)</td><td align="center" rowspan="1" colspan="1">23 (18&#x02013;29)</td><td align="center" rowspan="1" colspan="1">0.072</td></tr><tr><td align="left" rowspan="1" colspan="1">Pre&#x02010;EUS dose of analgesics, mg, median (IQR)</td><td align="center" rowspan="1" colspan="1">15 (15&#x02010;15)</td><td align="center" rowspan="1" colspan="1">35 (35&#x02010;35)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Total dose of analgesics, mg, median (IQR)</td><td align="center" rowspan="1" colspan="1">15 (15&#x02010;15)</td><td align="center" rowspan="1" colspan="1">35 (35&#x02010;35)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Pre&#x02010;EUS dose of midazolam, mg/body weight, median (IQR)</td><td align="center" rowspan="1" colspan="1">0.058 (0.048&#x02013;0.069)</td><td align="center" rowspan="1" colspan="1">0.050 (0.043&#x02013;0.061)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Total dose of midazolam, mg/body weight, median (IQR)</td><td align="center" rowspan="1" colspan="1">0.075 (0.061&#x02013;0.095)</td><td align="center" rowspan="1" colspan="1">0.068 (0.057&#x02013;0.081)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Administration of flumazenil, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1">32 (6.6)</td><td align="center" rowspan="1" colspan="1">33 (6.7)</td><td align="center" rowspan="1" colspan="1">0.898<xref rid="deo270048-tbl3-note-0004" ref-type="table-fn">
<sup>*</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Sedation&#x02010;related adverse events during EUS, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Discontinuation of EUS</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">1 (0.2)</td><td align="center" rowspan="1" colspan="1">1.000<xref rid="deo270048-tbl3-note-0005" ref-type="table-fn">
<sup>**</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Circulation</td><td align="center" rowspan="1" colspan="1">9 (1.9)</td><td align="center" rowspan="1" colspan="1">3 (0.6)</td><td align="center" rowspan="1" colspan="1">0.146<xref rid="deo270048-tbl3-note-0005" ref-type="table-fn">
<sup>**</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Respiration</td><td align="center" rowspan="1" colspan="1">4 (0.8)</td><td align="center" rowspan="1" colspan="1">2 (0.4)</td><td align="center" rowspan="1" colspan="1">0.682<xref rid="deo270048-tbl3-note-0005" ref-type="table-fn">
<sup>**</sup>
</xref>
</td></tr></tbody></table><table-wrap-foot><fn id="deo270048-tbl3-note-0001"><p>Abbreviations: EUS, endoscopic ultrasonography; IQR, interquartile range.</p></fn><fn id="deo270048-tbl3-note-0002"><p>Statistical significance was set at <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.05.</p></fn><fn id="deo270048-tbl3-note-0003"><p>Mann&#x02013;Whitney U&#x02010;test.</p></fn><fn id="deo270048-tbl3-note-0004"><label>*</label><p>Chi&#x02010;square test.</p></fn><fn id="deo270048-tbl3-note-0005"><label>**</label><p>Fisher's&#x000a0;exact test.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo270048-sec-0130"><title>Sedation&#x02010;related outcomes after EUS</title><p>The duration of stay in the recovery room was significantly shorter in the pethidine hydrochloride group than in the pentazocine group (median [IQR], 69&#x000a0;min [61&#x02013;81&#x000a0;min] vs. 77&#x000a0;min [65&#x02013;94&#x000a0;min]; <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001; Table&#x000a0;<xref rid="deo270048-tbl-0004" ref-type="table">4</xref>). The frequency of nausea or vomiting after EUS was significantly lower in the pethidine hydrochloride group than in the pentazocine group (0% [0/486] vs. 6.2% [29/486]; <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001). In addition, the frequency of readmission to the recovery room was significantly lower in the pethidine hydrochloride group than in the pentazocine group (0% [0/486] vs. 3.7% [18/486]; <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001). All the cases who were readmitted to the recovery room complained of nausea or vomiting, and three cases also complained of dizziness. In one case, the patient was hospitalized for persistent nausea and could not return home on the day of EUS. Finally, the multivariate analysis to examine factors associated with readmission showed that pentazocine (OR, 17.682; 95% CI, 6.066&#x02013;51.542; <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001) and female sex (OR, 8.220; 95% CI, 3.482&#x02013;19.404; <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001) were identified as independent factors (Table <xref rid="deo270048-supitem-0001" ref-type="supplementary-material">S1</xref>).</p><table-wrap position="float" id="deo270048-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>Sedation&#x02010;related outcomes after endoscopic ultrasonography (after propensity score matching).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<p>Pentazocine</p>
<p>
<italic toggle="yes">N</italic>&#x000a0;= 486</p>
</th><th align="left" rowspan="1" colspan="1">
<p>Pethidine hydrochloride</p>
<p>
<italic toggle="yes">N</italic>&#x000a0;= 486</p>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Duration of stay in the recovery room, minutes, median (IQR)</td><td align="center" rowspan="1" colspan="1">77 (65&#x02013;94)</td><td align="center" rowspan="1" colspan="1">69 (61&#x02013;81)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea or vomiting after EUS, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1">29 (6.2)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Readmission to the recovery room, n (%)</td><td align="center" rowspan="1" colspan="1">18 (3.7)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="deo270048-tbl4-note-0001"><p>Abbreviations: EUS, endoscopic ultrasonography; IQR, interquartile range.</p></fn><fn id="deo270048-tbl4-note-0002"><p>Statistical significance was set at <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.05.</p></fn><fn id="deo270048-tbl4-note-0003"><p>Mann&#x02013;Whitney U&#x02010;test.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec id="deo270048-sec-0140"><title>DISCUSSION</title><p>Sedation methods that provide the sedation levels required for diagnostic EUS have not been well studied.<xref rid="deo270048-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="deo270048-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> There is no specific evidence to support the level of sedation required for diagnostic EUS. This EUS is often performed in an outpatient setting because it is quicker to perform and is usually better tolerated than therapeutic EUS or endoscopic retrograde cholangiopancreatography. Moderate sedation is the most common practice when performing diagnostic EUS,<xref rid="deo270048-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> and it is most often achieved through intravenous bolus delivery of benzodiazepines and opioid analgesics.<xref rid="deo270048-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="deo270048-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> The combination of sedatives and opioid analgesics provides satisfactory moderate sedation because opioid analgesics alone provide mild sedation with analgesia.<xref rid="deo270048-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="deo270048-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> However, published data have suggested that a combination of sedatives and opioid analgesics may increase the likelihood of sedation&#x02010;related adverse events.<xref rid="deo270048-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="deo270048-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="deo270048-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Several sedation&#x02010;related adverse events have been reported, including hypotension, desaturation, bradycardia, hypertension, respiratory depression, vomiting, and cardiac and respiratory arrest.<xref rid="deo270048-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="deo270048-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> In a review of 40 patients who underwent EUS with a combination of midazolam and pethidine hydrochloride, no serious complications occurred; however, minor complications, such as hypoxemia, occurred in 51% of cases.<xref rid="deo270048-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> When midazolam and pentazocine were used during radiofrequency ablation, airway insertion was required in 18% of patients.<xref rid="deo270048-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Here, sedation&#x02010;related adverse events during diagnostic EUS were&#x000a0;&#x0003c;&#x000a0;2% in both the pentazocine and pethidine hydrochloride groups. However, the pentazocine group required a considerably longer time to recover from sedation than the pethidine hydrochloride group. Additionally, the pentazocine group required a higher dose of midazolam to achieve moderate sedation, suggesting a greater sedative requirement compared to the pethidine group. Nevertheless, the small difference in midazolam dosage is unlikely to have significantly contributed to the prolonged recovery time. These results suggest that the combination of midazolam and pethidine hydrochloride is a more suitable sedation method for outpatient EUS than the combination of midazolam and pentazocine.</p><p>Patients sometimes experience nausea or vomiting after undergoing EUS in the recovery room. Opioid analgesics can also cause nausea and vomiting.<xref rid="deo270048-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> The analgesic effects of opioids are mediated by activation of three receptor subtypes: mu (&#x003bc;), delta (&#x003b4;), and kappa (&#x003ba;).<xref rid="deo270048-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="deo270048-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> Pethidine hydrochloride acts on the &#x003bc; receptors. Pentazocine is an antagonist of &#x003bc; receptors and a stimulator of &#x003ba; receptors. In the present study, the frequencies of nausea or vomiting and readmission to the recovery room were markedly lower in the pethidine hydrochloride group than in the pentazocine group. None of the cases in the pethidine hydrochloride group complained of nausea or vomiting or were readmitted to the recovery room. It has been suggested that differences in receptor action may be associated with the frequency of side effects.<xref rid="deo270048-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="deo270048-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>
</p><p>In the present study, we employed the hospital's own discharge criteria. Typical discharge criteria include the Aldrete scoring system and modified post&#x02010;anesthesia discharge scoring system. These are based on clinical criteria such as respiration, oxygen saturation, blood pressure, and level of consciousness.<xref rid="deo270048-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="deo270048-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> However, these discharge criteria do not include the rest time after the completion of the examination, which makes them difficult to use in clinical practice. In many cases, the discharge criteria developed by each facility are used to determine whether a patient is ready for discharge.<xref rid="deo270048-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> Our discharge criteria largely aligned with the Aldrete scoring system and modified post&#x02010;anesthesia discharge scoring system, and the minimum rest time after the completion of EUS was set at 45&#x000a0;min, which is considered a reasonable discharge criterion.</p><p>Propofol sedation may be better for diagnostic EUS than a combination of sedatives and analgesics.<xref rid="deo270048-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="deo270048-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="deo270048-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Propofol is a short&#x02010;acting sedative that potentiates gamma&#x02010;aminobutyric acid activity in the central nervous system. Midazolam, pethidine hydrochloride, and propofol all have an onset of action within approximately 5&#x000a0;min, but the durations of the effect are 15&#x02013;80&#x000a0;min for midazolam and 60&#x02013;180&#x000a0;min for pethidine hydrochloride, whereas that of propofol is 4&#x02013;8&#x000a0;min.<xref rid="deo270048-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Sedation with propofol has similar rates of sedation&#x02010;related adverse effects, higher patient satisfaction, shorter time to sedation, and shorter recovery time than sedation with a combination of midazolam and pethidine hydrochloride for diagnostic EUS.<xref rid="deo270048-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="deo270048-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="deo270048-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="deo270048-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> However, the use of propofol requires supervision by an anesthesiologist or a physician trained in anesthesia, making it difficult to use propofol in outpatients.<xref rid="deo270048-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="deo270048-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>, <xref rid="deo270048-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>
</p><p>This study has some limitations. First, this study is a retrospective single&#x02010;center observational study that does not include data on patient comorbidities or detailed patient backgrounds. Thus, further multicenter, large&#x02010;scale studies are required. Second, operator and patient satisfaction were not assessed. Therefore, it is difficult to evaluate whether the appropriate level of sedation was maintained during diagnostic EUS. Third, the median age of cases included in this study is 69 years, which is relatively young. Sedated endoscopy should be carefully discussed in older adult patients because of the increased risk of sedation&#x02010;related adverse events caused by the combination of sedatives and analgesics.<xref rid="deo270048-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="deo270048-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="deo270048-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p><p>In conclusion, using propensity score matching, this study revealed that the combination of midazolam and pethidine hydrochloride is a more favorable sedation approach than the combination of midazolam and pentazocine for diagnostic EUS in outpatients.</p></sec><sec sec-type="COI-statement" id="deo270048-sec-0160"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare no conflict of interest.</p></sec><sec id="deo270048-sec-0190"><title>ETHICS STATEMENT</title><p>This study was approved by the Institutional Review Board of Osaka International Cancer Institute (approval number: 20117&#x02010;6) and was designed and executed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. Informed consent to participate in the study was waived in accordance with the Japanese government's Ethical Guidelines for Medical and Health Research Involving Human Subjects, which allow an opt&#x02010;out approach for studies based on existing, anonymized information that do not include human biological specimens.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="deo270048-supitem-0001" position="float" content-type="local-data"><caption><p>TABLE S1 Univariate and multivariate analysis of factors associated with readmission to the recovery room.</p></caption><media xlink:href="DEO2-5-e70048-s001.docx"/></supplementary-material></sec></body><back><ack id="deo270048-sec-0150"><title>ACKNOWLEDGMENTS</title><p>We express our sincere gratitude to the endoscopy staff at our institute. We also appreciate the English language editing assistance provided by Editage (<ext-link xlink:href="http://www.editage.jp" ext-link-type="uri">www.editage.jp</ext-link>).</p></ack><sec sec-type="data-availability" id="deo270048-sec-0180"><title>DATA AVAILABILITY STATEMENT</title><p>Data supporting the findings of this study are available upon reasonable request from the corresponding author.</p></sec><ref-list id="deo270048-bibl-0001"><title>REFERENCES</title><ref id="deo270048-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="deo270048-cit-0001">
<string-name>
<surname>Siegel</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Giaquinto</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Jemal</surname>
<given-names>A</given-names>
</string-name>. <article-title>Cancer statistics, 2024</article-title>. <source>CA: A Cancer Journal for Clinicians</source>
<year>2024</year>; <volume>74</volume>: <fpage>12</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">38230766</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="deo270048-cit-0002">
<string-name>
<surname>Ohtsuka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fernandez&#x02010;Del Castillo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Furukawa</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>International evidence&#x02010;based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas</article-title>. <source>Pancreatology</source>
<year>2024</year>; <volume>24</volume>: <fpage>255</fpage>&#x02013;<lpage>270</lpage>.<pub-id pub-id-type="pmid">38182527</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="deo270048-cit-0003">
<string-name>
<surname>Khorana</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Mangu</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>Berlin</surname>
<given-names>J</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline</article-title>. <source>J Clin Oncol</source>
<year>2016</year>; <volume>34</volume>: <fpage>2541</fpage>&#x02013;<lpage>2556</lpage>.<pub-id pub-id-type="pmid">27247221</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="deo270048-cit-0004">
<string-name>
<surname>Okusaka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yoshida</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Clinical practice guidelines for pancreatic cancer 2022 from the Japan Pancreas Society: A synopsis</article-title>. <source>Int J Clin Oncol</source>
<year>2023</year>; <volume>28</volume>: <fpage>493</fpage>&#x02013;<lpage>511</lpage>.<pub-id pub-id-type="pmid">36920680</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="deo270048-cit-0005">
<string-name>
<surname>Omoto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kitano</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fukasawa</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Tissue harmonic versus contrast&#x02010;enhanced harmonic endoscopic ultrasonography for the diagnosis of pancreatic tumors: Prospective multicenter study</article-title>. <source>Dig Endosc</source>
<year>2022</year>; <volume>34</volume>: <fpage>198</fpage>&#x02013;<lpage>206</lpage>.<pub-id pub-id-type="pmid">33547825</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="deo270048-cit-0006">
<string-name>
<surname>Yang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Qiu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ren</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>You</surname>
<given-names>L</given-names>
</string-name>. <article-title>Early screening and diagnosis strategies of pancreatic cancer: A comprehensive review</article-title>. <source>Cancer Commun</source>
<year>2021</year>; <volume>41</volume>: <fpage>1257</fpage>&#x02013;<lpage>1274</lpage>.</mixed-citation></ref><ref id="deo270048-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="deo270048-cit-0007">
<string-name>
<surname>Yamashita</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yoshikawa</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kawaji</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Novel endoscopic ultrasonography imaging technique for visualizing microcirculation without contrast enhancement in subepithelial lesions: Prospective study</article-title>. <source>Dig Endosc</source>
<year>2021</year>; <volume>33</volume>: <fpage>955</fpage>&#x02013;<lpage>961</lpage>.<pub-id pub-id-type="pmid">33145842</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="deo270048-cit-0008">
<string-name>
<surname>Shintani</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Inatomi</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Okamoto</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Diagnostic accuracy of endoscopic ultrasonographic shear wave elastography for assessing early chronic pancreatitis using the Japanese diagnostic criteria 2019</article-title>. <source>DEN Open</source>
<year>2025</year>; <volume>5</volume>: <elocation-id>e387</elocation-id>.<pub-id pub-id-type="pmid">38868706</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="deo270048-cit-0009">
<string-name>
<surname>Overbeek</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Cahen</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Bruno</surname>
<given-names>MJ</given-names>
</string-name>. <article-title>The role of endoscopic ultrasound in the detection of pancreatic lesions in high&#x02010;risk individuals</article-title>. <source>Fam Cancer</source>
<year>2024</year>; <volume>23</volume>: 279&#x02010;293.</mixed-citation></ref><ref id="deo270048-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="deo270048-cit-0010">
<string-name>
<surname>Hijioka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Morizane</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Takaori</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Okusaka</surname>
<given-names>T</given-names>
</string-name>. <article-title>Study protocol for a multi&#x02010;institutional prospective surveillance study among kindreds with familial pancreatic cancer and individuals with hereditary pancreatic cancer syndrome: The Diamond study</article-title>. <source>Pancreatology</source>
<year>2022</year>; <volume>22</volume>: <fpage>534</fpage>&#x02013;<lpage>538</lpage>.<pub-id pub-id-type="pmid">35443912</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="deo270048-cit-0011">
<string-name>
<surname>Ikezawa</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Shigekawa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yamai</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Endoscopic biliary stenting as the risk factor for cholangitis after endoscopic ultrasound in patients with biliary strictures</article-title>. <source>J Gastroenterol Hepatol</source>
<year>2021</year>; <volume>36</volume>: <fpage>1263</fpage>&#x02013;<lpage>1266</lpage>.<pub-id pub-id-type="pmid">32955726</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="deo270048-cit-0012">
<string-name>
<surname>Tang</surname>
<given-names>RSY</given-names>
</string-name>. <article-title>Endoscopic evaluation of indeterminate biliary strictures: Cholangioscopy, endoscopic ultrasound, or both?</article-title>
<source>Dig Endosc</source>
<year>2024</year>; <volume>36</volume>: 778&#x02013;788.</mixed-citation></ref><ref id="deo270048-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="deo270048-cit-0013">
<string-name>
<surname>Sidhu</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Turnbull</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Haboubi</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>British Society of Gastroenterology guidelines on sedation in gastrointestinal endoscopy</article-title>. <source>Gut</source>
<year>2024</year>; <volume>73</volume>: <fpage>219</fpage>&#x02013;<lpage>245</lpage>.<pub-id pub-id-type="pmid">37816587</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="deo270048-cit-0014">
<string-name>
<surname>Vargo</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>DeLegge</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Feld</surname>
<given-names>AD</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Multisociety sedation curriculum for gastrointestinal endoscopy</article-title>. <source>Gastrointest Endosc</source>
<year>2012</year>; <volume>76</volume>: <fpage>e1</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">22624793</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="deo270048-cit-0015">
<string-name>
<surname>Gotoda</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Akamatsu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Abe</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Guidelines for sedation in gastroenterological endoscopy (second edition)</article-title>. <source>Dig Endosc</source>
<year>2021</year>; <volume>33</volume>: <fpage>21</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">33124106</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="deo270048-cit-0016">
<string-name>
<surname>Early</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Lightdale</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Vargo</surname>
<given-names>JJ</given-names>
<suffix>2nd</suffix>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Guidelines for sedation and anesthesia in GI endoscopy</article-title>. <source>Gastrointest Endosc</source>
<year>2018</year>; <volume>87</volume>: <fpage>327</fpage>&#x02013;<lpage>337</lpage>.<pub-id pub-id-type="pmid">29306520</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="deo270048-cit-0017">
<string-name>
<surname>Furuta</surname>
<given-names>TKM</given-names>
</string-name>, <string-name>
<surname>Ito</surname>
<given-names>T</given-names>
</string-name>. <article-title>6th report of endoscopic complications: Results of the Japan Gastroenterological Endoscopy Society survey from 2008 to 2012</article-title>. <source>Gastroenterol Endosc</source>
<year>2016</year>; <volume>58</volume>: <fpage>1466</fpage>&#x02013;<lpage>1491</lpage>.</mixed-citation></ref><ref id="deo270048-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="deo270048-cit-0018">
<string-name>
<surname>Terui</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Inomata</surname>
<given-names>M</given-names>
</string-name>. <article-title>Administration of additional analgesics can decrease the incidence of paradoxical reactions in patients under benzodiazepine&#x02010;induced sedation during endoscopic transpapillary procedures: Prospective randomized controlled trial</article-title>. <source>Dig Endosc</source>
<year>2013</year>; <volume>25</volume>: <fpage>53</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="pmid">23286257</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="deo270048-cit-0019">
<string-name>
<surname>Hashimoto</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yasunaga</surname>
<given-names>H</given-names>
</string-name>. <article-title>Theory and practice of propensity score analysis</article-title>. <source>Ann Clin Epidemiol</source>
<year>2022</year>; <volume>4</volume>: <fpage>101</fpage>&#x02013;<lpage>109</lpage>.<pub-id pub-id-type="pmid">38505253</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="deo270048-cit-0020">
<string-name>
<surname>Kanda</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Investigation of the freely available easy&#x02010;to&#x02010;use software &#x02018;EZR&#x02019; for medical statistics</article-title>. <source>Bone Marrow Transplant</source>
<year>2013</year>; <volume>48</volume>: <fpage>452</fpage>&#x02013;<lpage>458</lpage>.<pub-id pub-id-type="pmid">23208313</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="deo270048-cit-0021">
<string-name>
<surname>Triantafillidis</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Merikas</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Nikolakis</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Papalois</surname>
<given-names>AE</given-names>
</string-name>. <article-title>Sedation in gastrointestinal endoscopy: Current issues</article-title>. <source>World J Gastroenterol</source>
<year>2013</year>; <volume>19</volume>: <fpage>463</fpage>&#x02013;<lpage>481</lpage>.<pub-id pub-id-type="pmid">23382625</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="deo270048-cit-0022">
<string-name>
<surname>Nishizawa</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yoshida</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Toyoshima</surname>
<given-names>O</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Risk factors for prolonged hospital stay after endoscopy</article-title>. <source>Clin Endosc</source>
<year>2021</year>; <volume>54</volume>: <fpage>851</fpage>&#x02013;<lpage>856</lpage>.<pub-id pub-id-type="pmid">33721977</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="deo270048-cit-0023">
<string-name>
<surname>Nishizawa</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sakitani</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Suzuki</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Adverse events associated with bidirectional endoscopy with midazolam and pethidine</article-title>. <source>J Clin Biochem Nutr</source>
<year>2020</year>; <volume>66</volume>: <fpage>78</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">32001961</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="deo270048-cit-0024">
<string-name>
<surname>Y&#x000fc;ksel</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Parlak</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>K&#x000f6;kl&#x000fc;</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ertugrul</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Tun&#x000e7;</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Sahin</surname>
<given-names>B</given-names>
</string-name>. <article-title>Conscious sedation during endoscopic retrograde cholangiopancreatography: Midazolam or midazolam plus meperidine?</article-title>
<source>Eur J Gastroenterol Hepatol</source>
<year>2007</year>; <volume>19</volume>: <fpage>1002</fpage>&#x02013;<lpage>1006</lpage>.<pub-id pub-id-type="pmid">18049171</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="deo270048-cit-0025">
<article-title>Practice Guidelines for Moderate Procedural Sedation and Analgesia 2018: A Report by the American Society of Anesthesiologists Task Force on Moderate Procedural Sedation and Analgesia, the American Association of Oral and Maxillofacial Surgeons, American College of Radiology, American Dental Association, American Society of Dentist Anesthesiologists, and Society of Interventional Radiology</article-title>. <source>Anesthesiology</source>
<year>2018</year>; <volume>128</volume>: <fpage>437</fpage>&#x02013;<lpage>479</lpage>.<pub-id pub-id-type="pmid">29334501</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="deo270048-cit-0026">
<string-name>
<surname>Dewitt</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>McGreevy</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sherman</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Imperiale</surname>
<given-names>TF</given-names>
</string-name>. <article-title>Nurse&#x02010;administered propofol sedation compared with midazolam and meperidine for EUS: A prospective, randomized trial</article-title>. <source>Gastrointest Endosc</source>
<year>2008</year>; <volume>68</volume>: <fpage>499</fpage>&#x02013;<lpage>509</lpage>.<pub-id pub-id-type="pmid">18561925</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="deo270048-cit-0027">
<string-name>
<surname>Nakano</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Torisu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nakagawa</surname>
<given-names>C</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Safety and efficacy of pentazocine&#x02010;midazolam combination for pain and anxiety relief in radiofrequency ablation therapy for hepatocellular carcinoma</article-title>. <source>JGH Open</source>
<year>2022</year>; <volume>6</volume>: <fpage>569</fpage>&#x02013;<lpage>576</lpage>.<pub-id pub-id-type="pmid">35928702</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="deo270048-cit-0028">
<string-name>
<surname>Gan</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Belani</surname>
<given-names>KG</given-names>
</string-name>, <string-name>
<surname>Bergese</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Fourth consensus guidelines for the management of postoperative nausea and vomiting</article-title>. <source>Anesth Analg</source>
<year>2020</year>; <volume>131</volume>: <fpage>411</fpage>&#x02013;<lpage>448</lpage>.<pub-id pub-id-type="pmid">32467512</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="deo270048-cit-0029">
<string-name>
<surname>Paul</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Rahmatullah</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Opioid analgesia and opioid&#x02010;induced adverse effects: A review</article-title>. <source>Pharmaceuticals</source>
<year>2021</year>; <volume>14</volume>: <fpage>1091</fpage>.<pub-id pub-id-type="pmid">34832873</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="deo270048-cit-0030">
<string-name>
<surname>Fillingim</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Gear</surname>
<given-names>RW</given-names>
</string-name>. <article-title>Sex differences in opioid analgesia: Clinical and experimental findings</article-title>. <source>Eur J Pain</source>
<year>2004</year>; <volume>8</volume>: <fpage>413</fpage>&#x02013;<lpage>425</lpage>.<pub-id pub-id-type="pmid">15324773</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="deo270048-cit-0031">
<string-name>
<surname>Ching Wong</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Cheung</surname>
<given-names>CW</given-names>
</string-name>. <article-title>Analgesic efficacy and adverse effects of meperidine in managing postoperative or labor pain: A narrative review of randomized controlled trials</article-title>. <source>Pain Physician</source>
<year>2020</year>; <volume>23</volume>: <fpage>175</fpage>&#x02013;<lpage>201</lpage>.<pub-id pub-id-type="pmid">32214301</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="deo270048-cit-0032">
<string-name>
<surname>Kuroiwa</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Handa</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Inomata</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>Y</given-names>
</string-name>. <article-title>The effect of pentazocine on nausea and vomiting following catheter ablation</article-title>. <source>Showa Univ J Med Sci</source>
<year>2020</year>; <volume>32</volume>: <fpage>103</fpage>&#x02013;<lpage>111</lpage>.</mixed-citation></ref><ref id="deo270048-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="deo270048-cit-0033">
<string-name>
<surname>Aldrete</surname>
<given-names>JA</given-names>
</string-name>. <article-title>Modifications to the postanesthesia score for use in ambulatory surgery</article-title>. <source>J Perianesth Nurs</source>
<year>1998</year>; <volume>13</volume>: <fpage>148</fpage>&#x02013;<lpage>155</lpage>.<pub-id pub-id-type="pmid">9801540</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="deo270048-cit-0034">
<string-name>
<surname>Palumbo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Tellan</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Perotti</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Pacil&#x000e8;</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Vietri</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Illuminati</surname>
<given-names>G</given-names>
</string-name>. <article-title>Modified PADSS (Post Anaesthetic Discharge Scoring System) for monitoring outpatients discharge</article-title>. <source>Ann Ital Chir</source>
<year>2013</year>; <volume>84</volume>: <fpage>661</fpage>&#x02013;<lpage>665</lpage>.<pub-id pub-id-type="pmid">23165318</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="deo270048-cit-0035">
<string-name>
<surname>Imagawa</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fujishiro</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Michida</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Mizokami</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Status of the use of &#x0201c;time out&#x0201d; just before procedure and &#x0201c;discharge criteria&#x0201d; after procedure with sedation, as perioperative management of esophagogastroduodenoscopy</article-title>. <source>Gastroenterol Endosc</source>
<year>2022</year>; <volume>64</volume>: <fpage>1039</fpage>&#x02013;<lpage>1047</lpage>.</mixed-citation></ref><ref id="deo270048-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="deo270048-cit-0036">
<string-name>
<surname>Wang</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>J</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>The use of propofol as a sedative agent in gastrointestinal endoscopy: A meta&#x02010;analysis</article-title>. <source>PLoS One</source>
<year>2013</year>; <volume>8</volume>: <elocation-id>e53311</elocation-id>.<pub-id pub-id-type="pmid">23308191</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="deo270048-cit-0037">
<string-name>
<surname>Vargo</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Zuccaro</surname>
<given-names>G</given-names>
<suffix>Jr.</suffix>
</string-name>, <string-name>
<surname>Dumot</surname>
<given-names>JA</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Gastroenterologist&#x02010;administered propofol versus meperidine and midazolam for advanced upper endoscopy: A prospective, randomized trial</article-title>. <source>Gastroenterology</source>
<year>2002</year>; <volume>123</volume>: <fpage>8</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">12105827</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="deo270048-cit-0038">
<string-name>
<surname>Kanno</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ohira</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Harada</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Safety and recipient satisfaction of propofol sedation in outpatient endoscopy: A 24&#x02010;hour prospective investigation using a questionnaire survey</article-title>. <source>Clin Endosc</source>
<year>2021</year>; <volume>54</volume>: <fpage>340</fpage>&#x02013;<lpage>347</lpage>.<pub-id pub-id-type="pmid">33302328</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="deo270048-cit-0039">
<string-name>
<surname>Viazis</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Vlachogiannakos</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Apostolopoulos</surname>
<given-names>P</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Sedation during endoscopic procedures: A Hellenic Society of Gastroenterology position statement</article-title>. <source>Ann Gastroenterol</source>
<year>2023</year>; <volume>36</volume>: <fpage>231</fpage>&#x02013;<lpage>243</lpage>.<pub-id pub-id-type="pmid">37144021</pub-id>
</mixed-citation></ref><ref id="deo270048-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="deo270048-cit-0040">
<string-name>
<surname>Dossa</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Megetto</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Yakubu</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>DDQ</given-names>
</string-name>, <string-name>
<surname>Baxter</surname>
<given-names>NN</given-names>
</string-name>. <article-title>Sedation practices for routine gastrointestinal endoscopy: A systematic review of recommendations</article-title>. <source>BMC Gastroenterol</source>
<year>2021</year>; <volume>21</volume>: <fpage>22</fpage>.<pub-id pub-id-type="pmid">33413147</pub-id>
</mixed-citation></ref></ref-list></back></article>